A Mother and Daughter Challenge Insulin Costs and Help North Dakota Win a $25 Monthly Copay Cap
Guest Contributor
In North Dakota’s Red River Valley, a quiet shift in the national debate over drug costs is taking shape. On a family farm that has survived more than a century, the Kritzberger family now grows sugar beets, soybeans, and grains, working hard to stay ahead of substantial debt. At the same time, they are living through a different kind of struggle that millions of Americans know well: the fight to afford insulin. Their story helps explain why support for insulin price caps and broader regulation of prescription drug prices is gaining traction across party lines.
For the Kritzbergers, the issue became urgent when their daughter Nina was diagnosed with Type 1 diabetes at just 7 years old. Her mother remembers sleeping by her bedside for two months, waking every two hours to test her blood sugar. A decade later, Nina is 17, juggling her school life and social activities with a relentless checklist of medical needs. She talks about making sure she always has insulin, a spare pump, a backup sensor, a traditional testing kit, and quick sources of sugar like sports drinks or glucose tablets. Missing a dose of insulin is not an inconvenience for her. It is a life-threatening emergency that could quickly land her in the hospital and, as she bluntly notes, could be fatal.

The financial side of this daily vigilance is equally stark. Even with health insurance, the Kritzbergers spend at least $8,000 out of pocket every year on diabetes drugs, supplies, and medical appointments. Families like theirs sit at the center of a broader crisis driven by soaring insulin prices. For years, many people with diabetes paid hundreds or even thousands of dollars annually for insulin. Some rationed doses or skipped them altogether, leading to serious complications and, in some cases, death. Patient advocates, including the American Diabetes Association, began sounding alarms as stories of preventable tragedy became impossible to ignore.
In response, a growing number of states have implemented insulin copay caps to limit what patients must spend each month. North Dakota is one of 29 states to enact such a measure. The policy caps out-of-pocket insulin costs at $25 a month for many patients covered by state-regulated health plans. This cap applies even when individuals have high deductibles that would usually require them to pay thousands of dollars before their insurance coverage fully activates. For families already under financial strain, the cap is meant to serve as a shield against sudden price spikes and ongoing uncertainty.

The political journey to get there reveals an unusual level of consensus. Traditionally, debates about healthcare costs split along familiar ideological lines, with Republicans more inclined toward free market approaches and Democrats more open to direct intervention. In this case, though, lawmakers in North Dakota and elsewhere began to conclude that the insulin market was not functioning in a way that protected patients. A Republican state senator, Sean Cleary, co-sponsored the cap and later reflected that families were facing impossible decisions about rationing essential medicine. That realization helped bridge typical partisan divides.
The push for caps did not emerge from nowhere. Colorado became the first state to introduce such a limit in 2019, setting a $100 cap on a 30-day insulin supply for people covered by certain state-regulated plans. At the federal level, a key step came in 2022 when President Joe Biden signed legislation capping insulin costs for Medicare beneficiaries at $35 a month. Efforts to extend a similar cap to people with private insurance did not succeed in Congress, but the debate helped spotlight the scale of the challenge and encouraged more states to act.
North Dakota’s path was particularly challenging at first. State senator Tim Mathern, one of only a handful of Democrats in the chamber, initially struggled to gain support for an insulin copay cap. Health insurers and the state chamber of commerce opposed the measure. They argued that making insulin cheaper at the pharmacy counter would simply raise premiums for everyone else and said new mandates moved away from the original intent of insurance. AARP, advocating for older adults in the state, countered that existing systems were not keeping drug costs manageable for people who needed insulin to live.
Opponents also tapped into a common belief among many lawmakers that government should not intervene heavily in markets. Advocates for the bill had to confront that skepticism directly. They highlighted a state program that had already capped insulin costs for public employees and noted that premiums in that program had not significantly increased. This evidence helped undercut fears that a broader cap would destabilize the insurance market for others.
Over time, frustration with the wider healthcare system seemed to reshape the conversation. Lawmakers from both parties reflected publicly on their unease with how pharmaceutical companies, insurers, and other industry players are rewarded in the current environment. Representative Carrie McLeod, a Republican and diabetes educator, noted that insurance was originally designed for catastrophic needs but now feels weighted by financial priorities that can overshadow patient care. As more legislators listened to people living with diabetes, including families who traveled hours to testify, the moral dimension of the debate became harder to ignore.
When the insulin cap finally came up for a vote in North Dakota, it passed with overwhelming bipartisan support. The new limit does not solve every affordability problem. State-level rules only reach certain health plans, while many large employer-sponsored plans fall under federal jurisdiction. Even so, the cap eases some of the day-to-day financial anxiety for families like the Kritzbergers and provides a measure of protection against future price hikes.
Nationally, the conversation is far from over. Polling from KFF suggests that about 7 in 10 U.S. adults believe there is not enough government regulation to limit the price of prescription drugs. Support is broad across party lines. A bipartisan group in Congress, which includes North Dakota Senator Kevin Cramer, is now considering a nationwide insulin price cap. Whether such a policy becomes law remains uncertain, but the momentum around it suggests that the question of how to protect patients from high drug prices is now shared ground rather than a sharply divisive issue.
Back in Hillsboro, the Kritzberger farm reflects another piece of this story. When a neighbor with brain cancer needed help harvesting sugar beets, local farmers stepped in to complete the work. That same sense of community carried families to the state Capitol as they testified about managing diabetes, balancing budgets, and trying to keep loved ones healthy. Their experiences helped show that debates over insulin price caps are not only about markets and mandates. They are also about connection, mutual responsibility, and the search for common ground in a system that often feels overwhelmingly complex.